Reported about 22 hours ago
AARP's new report indicates that prices for the top 25 drugs prescribed under Medicare Part D have nearly doubled since their introduction, significantly exceeding inflation rates. Notable examples include Merck's diabetes drug Janumet, which has increased by nearly 300% since its market debut in 2007. Despite ongoing negotiations for lower prices by Medicare, new weight-loss medications like Novo Nordisk's Ozempic are already seeing price hikes.
Source: YAHOO